Companies · Biotechnology

ChiScan, L.L.C.

CHANDLER · Biotechnology

Diligence memoA one-page analyst read on ChiScan, L.L.C. — recommendation, valuation, rhythm, risks.
$250K
Total raised · real
1
Rounds
Latest step-up
Top 95%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Nov 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

ChiScan, L.L.C. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.87× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
  • Within the normal band (87% of peer median) for its niche.
Dormant
  • Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

ChiScan, L.L.C. is one of 4293 Biotechnology companies tracked from CHANDLER. By capital raised it ranks in the long tail (ahead of 6% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2013-11-21 Raised $250K (real) Modeled valuation $14M (est)$250K$14MPre-Seed2013

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$250K · 2013

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$13.8M
Base estimate est.
$133K
Conservative case
$156.5M
Upside case
$1.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
12.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
12.6 yr
On record since
2013
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$250K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.6× of median
This company$250K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$13.8M
Sector median$64.2M

Raised more than 6% of sector peers (real $). Modeled value above 23% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #75 of 131.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Imanis Life Sciences, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Truminim, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Direct Spinal Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Universal Biosensors Inc · Pre-Seed Raised $985K · modeled $54.4M (est)One World Lab, Inc. · Pre-Seed Raised $981K · modeled $54.2M (est)Micropharma Ltd · Pre-Seed Raised $851K · modeled $47.0M (est)Symbiotic Health, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)CVUS Ventures, LP · Pre-Seed Raised $850K · modeled $46.9M (est)ConverGene LLC · Pre-Seed Raised $850K · modeled $46.9M (est)EternoGen Aesthetics, LLC · Pre-Seed Raised $939K · modeled $46.3M (est)Genomics USA, Inc. · Pre-Seed Raised $837K · modeled $46.2M (est)Immunetics, Inc. · Pre-Seed Raised $1.5M · modeled $46.1M (est)ChiScan, L.L.C. (this company) Raised $250K · modeled $13.8M (est)ChiScan, L.L.C.
CompanyStageRaised · realValue · estvs peer med.
Imanis Life Sciences, LLCPre-Seed$1.0M$55.2M3.48×
Truminim, LLCPre-Seed$1.0M$55.2M3.48×
Direct Spinal Therapeutics, Inc.Pre-Seed$1.0M$55.2M3.48×
Universal Biosensors IncPre-Seed$985K$54.4M3.43×
One World Lab, Inc.Pre-Seed$981K$54.2M3.42×
Micropharma LtdPre-Seed$851K$47.0M2.96×
Symbiotic Health, Inc.Pre-Seed$850K$46.9M2.96×
CVUS Ventures, LPPre-Seed$850K$46.9M2.96×
ConverGene LLCPre-Seed$850K$46.9M2.96×
EternoGen Aesthetics, LLCPre-Seed$939K$46.3M2.92×
Genomics USA, Inc.Pre-Seed$837K$46.2M2.92×
Immunetics, Inc.Pre-Seed$1.5M$46.1M2.91×
ChiScan, L.L.C. this companyPre-Seed$250K$13.8M0.87×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$250K2013-11-21$1.4M$13.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$250K2013-11-21
    • First recorded raise — entered as Pre-Seed.
Intelligence
Modeled next raise
$400K
Modeled next size est.range $260K$640K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Huan Truong2013-11
Registry & provenance

ChiScan, L.L.C. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1609456
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Acela Biomedical, LLCBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
Alacrity Biosciences IncBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
ANGLE plcBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
BioMedFlex - Spine, LLCBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
BoProcess, LLCBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
Cemines IncBiotechnologyPre-Seed$250K$13.8Msame sector · same stage
CHIP Diagnostics, Inc.BiotechnologyPre-Seed$250K$13.8Msame sector · same stage
Combined Therapeutics, Inc.BiotechnologyPre-Seed$250K$13.8Msame sector · same stage
Frequently asked
How much funding has ChiScan, L.L.C. raised?
ChiScan, L.L.C. has raised approximately $250K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is ChiScan, L.L.C.'s estimated valuation?
Provath's modeled valuation for ChiScan, L.L.C. is approximately $13.8M (modeled range $133K–$156.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ChiScan, L.L.C. at?
ChiScan, L.L.C.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Nov 21.
What does ChiScan, L.L.C. do and where is it based?
ChiScan, L.L.C. operates in the Biotechnology sector, based in CHANDLER.
Explore related

See where ChiScan, L.L.C. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ChiScan, L.L.C., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.